Millennium, Abbott Labs Pen $250M Deal to Discover Obesity, Diabetes Drugs | GenomeWeb

NEW YORK, March 12 – Abbott Laboratories and Millennium Pharmaceuticals said Monday that they agreed to enter a five-year, $250 million strategic alliance to jointly discover and develop obesity and diabetes drugs.

Under the terms of the agreement, Abbott of Abbott Park, Ill., said it would purchase $250 million worth of Millennium’s common stock. Abbott will acquire $50 million at the closing of the deal and the remaining $200 million over the next two years. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genes involved in histone deacetylation in Arabidopsis, effects of pathogenic presenilin-1 mutations, and more.

After a study finds DNA from antibiotic-resistant bacteria in Beijing smog, residents there worry, according to the New York Times.

Canada begins its search for a chief government science advisor, Nature News reports.

A company is using facial recognition tools to identify genetic disorders from pictures, Technology Review reports.